| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/06/2004 | US20040086555 Plaster containing felbinac |
| 05/06/2004 | US20040086554 Anti-inflammatory, analgesic plaster containing felbinac for the purpose of curing lumbago, myalgia, periarthritis, and so on |
| 05/06/2004 | US20040086552 Transdermal therapeutic system for highly dispersed silicon dioxide |
| 05/06/2004 | US20040086551 Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl |
| 05/06/2004 | US20040086548 Shape-retentive hydrogel particle aggregates and their uses |
| 05/06/2004 | US20040086546 Breath freshening and oral cleansing product with cinnamaldehyde |
| 05/06/2004 | US20040086544 Polymers with bioactive agents |
| 05/06/2004 | US20040086539 Quick water-dissolving film containing cosmetic, aromatic, pharmaceutical or food substances |
| 05/06/2004 | US20040086537 Comprises a chymase inhibitor as the active ingredient |
| 05/06/2004 | US20040086536 Comprising an anticholinergic agent and an NO donor as the active ingredients |
| 05/06/2004 | US20040086532 Mucoadhesive nanoparticulate systems, including liposomes and polymeric nanoparticles |
| 05/06/2004 | US20040086531 Botulinum toxin oral formulation, wherein carrier is formulated to release therapeutic amounts in a gastrointestinal tract of a patient with a gastric ulcer without a significant immune system response |
| 05/06/2004 | US20040086517 Porous, implantable device containing a fibrous support and at least one antigen |
| 05/06/2004 | US20040086493 That can be polymerized in contact with living cells and tissues, and in a very short time period that can be polymerized in contact with living cells and tissues, and in a very short time period. |
| 05/06/2004 | US20040086479 Can be chemically modified for different biomedical applications such as tissue engineering applications, wound management, contrast agents vehicles, drug delivery vehicles, etc. |
| 05/06/2004 | US20040086470 Stabilize oil-containing cosmetic preparations irrespective of the particle size of the pearlizing concentrates and without addition of polymers or inorganic carriers and hence would avoid separation |
| 05/06/2004 | US20040086465 Aerosol suspension formulations which are free of chlorofluorocarbons comprising mometasone furoate, a dry powder surfactant and HFA 227, |
| 05/06/2004 | US20040086464 Medicaments |
| 05/06/2004 | US20040086463 Comprising sodium hypochlorite, one or more of sodium chloride and sodium bromide; and optionally one or more of zinc gluconate, and glycerine or propylene glycol |
| 05/06/2004 | US20040086462 Radio-opaque polymer biomaterials |
| 05/06/2004 | US20040086461 Radio-opaque polymer biomaterials |
| 05/06/2004 | US20040086459 Efficient for back scattering ultrasound energy |
| 05/06/2004 | US20040086458 Radio-opaque polymer biomaterials |
| 05/06/2004 | EP1415934A1 Ring for an aerosol valve |
| 05/06/2004 | EP1415663A1 Sustained release hgf hydrogel preparations |
| 05/06/2004 | EP1415654A1 Enhancedly-solubilized beta-hydroxy acids and higher potency skin peels formulated therefrom |
| 05/06/2004 | EP1415649A1 Transdermal therapeutic system comprising oxybutynin |
| 05/06/2004 | EP1415648A1 Lyophilizing composition of drug-encapsulating polymer micelle and method for preparation thereof |
| 05/06/2004 | EP1415647A1 "Long-acting beta-2 agonists ultrafine formulations" |
| 05/06/2004 | EP1415646A1 Gel comprising antimicrobial extract as an adjunct in the treatment of periodontitis |
| 05/06/2004 | EP1414843A1 Novel dammarane sapogenins, their use as anti-cancer agents, and a process for producing same |
| 05/06/2004 | EP1414784A2 Amphiphilic star-like macromolecules for drug delivery |
| 05/06/2004 | EP1414498A2 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 05/06/2004 | EP1414497A1 Novel microemulsion and micelle systems for solubilizing drugs |
| 05/06/2004 | EP1414496A1 Oral pharmaceutical composition containing a combinaition of ppar-alpha and a hmg-coa reductase inhibitor |
| 05/06/2004 | EP1414493A2 Oral immunoglobulin treatment for inflammatory bowel disease |
| 05/06/2004 | EP1414490A1 Immunomodulatory oligonucleotide formulations and methods for use thereof |
| 05/06/2004 | EP1414479A1 Peptide for regulation of tissue plasminogen activator |
| 05/06/2004 | EP1414478A2 Inhibition of neurodegeneration |
| 05/06/2004 | EP1414470A1 Micronutrient phosphates as dietary and health supplements |
| 05/06/2004 | EP1414468A1 Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders |
| 05/06/2004 | EP1414466A1 Combinations for the treatment of inflammatory disorders |
| 05/06/2004 | EP1414462A2 Treatment of renal fibrosis |
| 05/06/2004 | EP1414459A1 Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| 05/06/2004 | EP1414458A1 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 05/06/2004 | EP1414454A1 Paroxetine glycyrrhizinate |
| 05/06/2004 | EP1414452A1 Novel substituted benzimidazole dosage forms and method of using same |
| 05/06/2004 | EP1414451A1 Opioid agonist formulations with releasable and sequestered antagonist |
| 05/06/2004 | EP1414448A1 Transdermal therapeutic system (reservoir-tts) for using pramipexole and ropinirole |
| 05/06/2004 | EP1414439A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
| 05/06/2004 | EP1414435A1 Crystalline composition containing escitalopram |
| 05/06/2004 | EP1414433A1 Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
| 05/06/2004 | EP1414420A1 Method for the continuous production and coating of self-adhesive compounds on the basis of sbc that includes at least one pharmaceutically active substance |
| 05/06/2004 | EP1414419A1 Pharmaceutical formulations comprising ketoconazole |
| 05/06/2004 | EP1414418A1 Compositions and methods to prevent abuse of opioids |
| 05/06/2004 | EP1414417A4 Pharmaceutical formulation |
| 05/06/2004 | EP1414417A1 Pharmaceutical formulation |
| 05/06/2004 | EP1414416A2 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| 05/06/2004 | EP1414415A2 Nutritional supplements and methods of using same |
| 05/06/2004 | EP1414414A1 Process of thermodynamical activation of water-insoluble drugs loaded into cross-linked polymers |
| 05/06/2004 | EP1414413A1 Compositions and methods to prevent abuse of opioids |
| 05/06/2004 | EP1414412A2 Composition based on lipid lamellar vesicles incorporating at least a dhea compound |
| 05/06/2004 | EP1414411A1 Pulmonary formulation comprising silicon particles |
| 05/06/2004 | EP1414410A1 Nanoparticulate formulations of fenofibrate |
| 05/06/2004 | EP1414409A1 Stabilized oral suspension formulation |
| 05/06/2004 | EP1414408A1 Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt |
| 05/06/2004 | EP1414407A2 Dosage forms comprising particles containing active ingredient for application on the skin or mucous membrane |
| 05/06/2004 | EP1414406A2 A bioactive agent delivering system comprised of microparticules within a biodegradable to improve release profiles |
| 05/06/2004 | EP1414390A1 Nanocapsules containing a steroid for cosmetic compositions |
| 05/06/2004 | EP1414317A2 Edible articles that include edible optical elements and methods for producing same |
| 05/06/2004 | EP1369122A4 Anticancer agent |
| 05/06/2004 | EP1226438B1 Composite nanospheres and their conjugates with biomolecules |
| 05/06/2004 | EP1194153B1 Taste masked pharmaceutical liquid formulations |
| 05/06/2004 | EP1181027B1 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 05/06/2004 | EP1137409B1 Compositions and methods for amelioration of human female sexual dysfunction |
| 05/06/2004 | EP1105139B1 Ophthalmic solution with tetracycline for topical treatment of dry eye disease |
| 05/06/2004 | EP1060719B1 Medical pressure-sensitive adhesive tape |
| 05/06/2004 | EP1056443B1 Butorphanol sustained release formulations |
| 05/06/2004 | EP1009390A4 Prolonged anesthesia in joints and body spaces |
| 05/06/2004 | EP0999826B1 Self-emulsifying formulation for lipophilic compounds |
| 05/06/2004 | EP0980203A4 Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases |
| 05/06/2004 | EP0918542B1 Use of (meth)acrylic acid copolymers to increase the permeability of mucous membranes |
| 05/06/2004 | EP0869776B1 Stabilised nanoparticles capable of being filtered under sterile conditions |
| 05/06/2004 | EP0812209B1 Cochleate delivery vehicles for biologically relevant molecules |
| 05/06/2004 | EP0804160B2 Compositions for applying active substances to or through the skin |
| 05/06/2004 | DE19649534B4 Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern Packaging of composite material for packaging active substance patches |
| 05/06/2004 | DE10250088A1 Gegen Missbrauch gesicherte Darreichungsform Abuse-proofed dosage form |
| 05/06/2004 | DE10250087A1 Gegen Missbrauch gesicherte Darreichungsform Abuse-proofed dosage form |
| 05/06/2004 | DE10250084A1 Gegen Missbrauch gesicherte Darreichungsform Abuse-proofed dosage form |
| 05/06/2004 | DE10249600A1 Invertebrate-based medicinal preparation, encases live caterpillar in bread dough, for release in large intestine to stimulate immune system and bring about healing |
| 05/06/2004 | DE10248601A1 Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems A pharmaceutical composition for endonasal administration in the treatment of diseases and disorders of the central nervous system |
| 05/06/2004 | DE10248575A1 Chiltosanpellets Chiltosanpellets |
| 05/06/2004 | DE10244914A1 Apparatus with nanodevice for controlling charged particle flow in electrolytes comprises electrolytic bath container divided by polymeric foil, asymmetric pore, electrically conductive layer and gate voltage supply |
| 05/06/2004 | CA2503539A1 Topical skin care composition |
| 05/06/2004 | CA2503391A1 Immediate release topical pharmaceutical formulation for enhancement of female sexual desire and responsiveness |
| 05/06/2004 | CA2503385A1 Capsule and film-forming composition comprising gum arabic |
| 05/06/2004 | CA2503383A1 Extended, controlled release pharmaceutical compositions comprising charged polymers |
| 05/06/2004 | CA2503380A1 Pharmaceutical compositions containing venlafaxine |
| 05/06/2004 | CA2503284A1 Sustained release l-arginine formulations and methods of manufacture and use |
| 05/06/2004 | CA2503193A1 Method and system for intravesicular delivery of therapeutic agents |